Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells $73,458.00 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar sold 10,494 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $7.00, for a total transaction of $73,458.00. Following the sale, the director owned 2,836,098 shares in the company, valued at approximately $19,852,686. This trade represents a 0.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Kush Parmar also recently made the following trade(s):

• On Monday, August 10th, Kush Parmar sold 92,444 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.00, for a total value of $647,108.00.
• On Friday, August 7th, Kush Parmar sold 52,317 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.85, for a total value of $358,371.45.
• On Friday, July 31st, Kush Parmar sold 1,718 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.85, for a total value of $11,768.30.
• On Thursday, July 30th, Kush Parmar sold 114,756 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.93, for a total value of $795,259.08.

Entrada Therapeutics Stock Up 1.2%

TRDA stock traded up $0.08 during mid-day trading on Monday, reaching $6.95. The company had a trading volume of 411,770 shares, compared to its average volume of 464,800. Entrada Therapeutics, Inc. has a one year low of $4.93 and a one year high of $16.45. The stock’s 50-day simple moving average is $6.86 and its two-hundred day simple moving average is $9.68. The stock has a market capitalization of $270.63 million, a P/E ratio of -1.76 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. The firm had revenue of $0.90 million during the quarter, compared to the consensus estimate of $2.32 million. On average, research analysts forecast that Entrada Therapeutics, Inc. will post -4.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Entrada Therapeutics

A number of institutional investors have recently modified their holdings of the company. State of Wyoming bought a new position in Entrada Therapeutics in the 2nd quarter worth $37,000. Russell Investments Group Ltd. grew its holdings in shares of Entrada Therapeutics by 72.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after purchasing an additional 3,707 shares in the last quarter. Occudo Quantitative Strategies LP bought a new stake in Entrada Therapeutics in the 2nd quarter valued at $68,000. Jain Global LLC acquired a new position in Entrada Therapeutics in the third quarter worth about $69,000. Finally, IHT Wealth Management LLC bought a new position in shares of Entrada Therapeutics during the 2nd quarter worth approximately $72,000. Institutional investors own 86.39% of the company’s stock.

Wall Street Analysts Forecast Growth

TRDA has been the subject of several recent analyst reports. Guggenheim decreased their price objective on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a report on Monday, June 8th. HC Wainwright lowered shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. Weiss Ratings downgraded Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Finally, Roth Capital set a $10.00 price objective on shares of Entrada Therapeutics in a research note on Friday, May 8th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $17.50.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.